Compare BIO-TECHNE Corp (TECH) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs iShares 10 20 Year Treasury Bond ETF — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while iShares 10 20 Year Treasury Bond ETF trades at $97.83. The key difference: BIO-TECHNE Corp pays a 0.45% dividend while iShares 10 20 Year Treasury Bond ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| TECH | TLH | |
|---|---|---|
Market Cap | $11.16B | — |
Sector | Health | Fixed Income |
52-Week High | $72.12 | $105.36 |
52-Week Low | $43.31 | $97.13 |
Enterprise Value | $11.24B | — |
Dividend Yield | 0.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
TLH trades at $98.13, down 0.56% today amid a bearish technical signal. The stock faces selling pressure with moving averages indicating a downtrend, while oscillators remain neutral. Recent dividends of $0.41 and $0.36 for H1-26 and H2-26 signal shareholder returns, but key valuation and profitability ratios are unavailable, limiting fundamental clarity.
The outlook is cautious due to bearish technicals and lack of financial metrics. Risks include market volatility from geopolitical tensions and Fed policy uncertainty. Investors need updated earnings and guidance to assess growth potential amid macroeconomic headwinds highlighted in recent financial news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
